These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 11286939)
1. Tumorigenesis in neurofibromatosis: new insights and potential therapies. Reed N; Gutmann DH Trends Mol Med; 2001 Apr; 7(4):157-62. PubMed ID: 11286939 [TBL] [Abstract][Full Text] [Related]
2. The neurofibromatoses: when less is more. Gutmann DH Hum Mol Genet; 2001 Apr; 10(7):747-55. PubMed ID: 11257108 [TBL] [Abstract][Full Text] [Related]
3. The genetic and molecular pathogenesis of NF1 and NF2. Yohay KH Semin Pediatr Neurol; 2006 Mar; 13(1):21-6. PubMed ID: 16818172 [TBL] [Abstract][Full Text] [Related]
6. New insights into the neurofibromatoses. Gutmann DH Curr Opin Neurol; 1994 Apr; 7(2):166-71. PubMed ID: 8019663 [TBL] [Abstract][Full Text] [Related]
7. Mouse models of neurofibromatosis 1 and 2. Gutmann DH; Giovannini M Neoplasia; 2002; 4(4):279-90. PubMed ID: 12082543 [TBL] [Abstract][Full Text] [Related]
8. Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis. Tamura R Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072574 [TBL] [Abstract][Full Text] [Related]
13. A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor. Hirokawa Y; Tikoo A; Huynh J; Utermark T; Hanemann CO; Giovannini M; Xiao GH; Testa JR; Wood J; Maruta H Cancer J; 2004; 10(1):20-6. PubMed ID: 15000491 [TBL] [Abstract][Full Text] [Related]
14. Neurofibromatosis 1: closing the GAP between mice and men. Dasgupta B; Gutmann DH Curr Opin Genet Dev; 2003 Feb; 13(1):20-7. PubMed ID: 12573431 [TBL] [Abstract][Full Text] [Related]
15. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications. Gottfried ON; Viskochil DH; Couldwell WT Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723 [TBL] [Abstract][Full Text] [Related]
16. The promise of signal transduction in genetically driven sarcomas of the nerve. Kim A; Pratilas CA Exp Neurol; 2018 Jan; 299(Pt B):317-325. PubMed ID: 28859862 [TBL] [Abstract][Full Text] [Related]
17. [Neurofibromatosis type 2 (NF2)]. Araki N; Takeshima H; Saya H Gan To Kagaku Ryoho; 1997 Sep; 24(11):1427-31. PubMed ID: 9309136 [TBL] [Abstract][Full Text] [Related]
18. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma. Lau N; Feldkamp MM; Roncari L; Loehr AH; Shannon P; Gutmann DH; Guha A J Neuropathol Exp Neurol; 2000 Sep; 59(9):759-67. PubMed ID: 11005256 [TBL] [Abstract][Full Text] [Related]
19. Neurofibromatosis. McClatchey AI Annu Rev Pathol; 2007; 2():191-216. PubMed ID: 18039098 [TBL] [Abstract][Full Text] [Related]
20. Neurofibromatosis type 1 peripheral nerve tumors: aberrant activation of the Ras pathway. Feldkamp MM; Angelov L; Guha A Surg Neurol; 1999 Feb; 51(2):211-8. PubMed ID: 10029430 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]